search
Back to results

Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery

Primary Purpose

Mitral Valve Replacement, Pulmonary Hypertension, Inhaled Milrinone

Status
Active
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Inhaled Milrinone
IV Milrinone
Sponsored by
Menoufia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mitral Valve Replacement focused on measuring Milrinone, Pulmonary Hypertension

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Severe mitral regurgitation and moderate or severe pulmonary hypertension Scheduled for mitral valve replacement surgery # Criteria of severe mitral regurgitation: Central jet MR >40% LA or holosystolic eccentric jet MR Vena contracta ≥ 0.7 cm Regurgitant volume ≥60 ml Regurgitant fraction ≥50% EROA ≥0.40 cm2 # Criteria of moderate and severe pulmonary hypertension: Moderate pulmonary hypertension; mean pulmonary artery pressure > 41 mmHg while, severe pulmonary hypertension; mean pulmonary artery pressure > 55 mmHg Mean pulmonary artery pressure > 40% of mean systemic blood pressure. Mean pulmonary artery pressure approximated from estimated systolic pulmonary artery pressure as following; mPAP= (estimated sPAP X 0.61) ± 2 Exclusion Criteria: Patients with multiple valve diseases -other than mitral valve-. Hemodynamic instability in the preoperative time (defined as acute requirement for vasoactive support or mechanical device). Contraindication to transesophageal echocardiography; esophageal stricture, tumor or diverticulum or active upper gastrointestinal bleeding Patients with hepatic or renal dysfunction. Patients with coagulopathy. Emergency surgeries.

Sites / Locations

  • Menoufia University Hospitals

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A (iMil)

Group B (IvMil)

Arm Description

Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter. Then pulmonary vascular resistance and systemic vascular resistance will be calculated after first dose ended by 2 minutes and after second dose ended by 15 minutes till stabilization of post CPB other variables like temperature and acid-base status, both measurements will be done while using inspired oxygen of 0.80.

Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.

Outcomes

Primary Outcome Measures

Change in pulmonary artery pressure

Secondary Outcome Measures

Incidence of systemic hypotension
Hemodynamic affection and need of vasopressors and inotropes.
Pulmonary vascular resistance versus systemic vascular resistance
Systemic vascular resistance: (MAP-CVP) x 80 / CO Pulmonary vascular resistance = (MPAP-LAP) X 80 / CO
Right ventricular function
Measured by tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler
Duration of mechanical ventilation
Need for mechanical circulatory support devices
Urine output
Length of intensive care (ICU) in stay

Full Information

First Posted
April 6, 2023
Last Updated
April 19, 2023
Sponsor
Menoufia University
search

1. Study Identification

Unique Protocol Identification Number
NCT05838846
Brief Title
Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery
Official Title
Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 1, 2023 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Menoufia University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This prospective double blinded randomized study aims to compare the effect of inhaled versus intravenous milrinone on the pulmonary vascular resistance in patients undergoing mitral valve replacement surgery. The primary outcome is to determine change in pulmonary artery pressure. The secondary outcomes include, Incidence of systemic hypotension. Hemodynamic affection and need of vasopressors and inotropes. Change in pulmonary vascular resistance versus systemic vascular resistance. Right ventricular function. Duration of mechanical ventilation. Need for mechanical circulatory support devices. Urine output Length of intensive care (ICU) in stay. As the investigators hypothesize that inhaled milrinone has a selective pulmonary vasodilator effect devoid of the systemic hypotension with the intravenous administration.
Detailed Description
Standard preoperative assessment for cardiac surgery will be done for all patients. Premedication will be given according to standard protocol in our university hospitals as follow bromazepam 3mg oral and ranitidine 150 mg orally in the night-before then another dose of ranitidine 150 mg 2 hours before arrival in operating theatre by small sips of clear liquid. On arrival to induction room wide bore IV access will be inserted using local anesthetic then arterial cannula in radial artery will be inserted the same manner using local anesthetic then in operating room routine monitoring including a five-lead electrocardiogram, pulse oximeter and invasive blood pressure will be attached. Anesthesia will be induced with midazolam 0.02 mg/kg and fentanyl 2-5 mcg/kg and muscle relaxation will be achieved by cis-atracurium 0.15 mg/kg. After tracheal intubation, central venous line and transesophageal echocardiography will be inserted, then anesthesia will be maintained throughout the procedure with morphine 20 mcg/kg/min, cis-atracurium 2 mcg/kg/min and sevoflurane 0.4% - 2% MAC. Ventilation will be adjusted to maintain end-tidal carbon dioxide in the range of 30-40 mmHg. During cardiopulmonary bypass, flow of 2.2 l/min/m2 will be achieved, 20 ml/kg cold blood cardioplegia will be given manually and pressure controlled at 20 - 30 min interval along with hot shot at start of weaning from CPB, temperature will be maintained at 32-34℃ and propofol 1% infusion at rate of 8 - 12ml/hr. In initial TEE study, baseline measures will be taken assessing left ventricular ejection fraction, and right ventricular hemodynamics represented by right ventricular function measured by [tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler] also, pulmonary vascular resistance and systemic vascular resistance will be calculated, plus patients hemodynamics (mean arterial blood pressure, heart rate) and inotropic score all measures will be recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitral Valve Replacement, Pulmonary Hypertension, Inhaled Milrinone, Intravenous Milrinone
Keywords
Milrinone, Pulmonary Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
116 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A (iMil)
Arm Type
Experimental
Arm Description
Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter. Then pulmonary vascular resistance and systemic vascular resistance will be calculated after first dose ended by 2 minutes and after second dose ended by 15 minutes till stabilization of post CPB other variables like temperature and acid-base status, both measurements will be done while using inspired oxygen of 0.80.
Arm Title
Group B (IvMil)
Arm Type
Active Comparator
Arm Description
Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
Intervention Type
Drug
Intervention Name(s)
Inhaled Milrinone
Intervention Description
Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization (21-23), inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
Intervention Type
Drug
Intervention Name(s)
IV Milrinone
Intervention Description
Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
Primary Outcome Measure Information:
Title
Change in pulmonary artery pressure
Time Frame
Intraoperative
Secondary Outcome Measure Information:
Title
Incidence of systemic hypotension
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Hemodynamic affection and need of vasopressors and inotropes.
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Pulmonary vascular resistance versus systemic vascular resistance
Description
Systemic vascular resistance: (MAP-CVP) x 80 / CO Pulmonary vascular resistance = (MPAP-LAP) X 80 / CO
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Right ventricular function
Description
Measured by tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Duration of mechanical ventilation
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Need for mechanical circulatory support devices
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Urine output
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)
Title
Length of intensive care (ICU) in stay
Time Frame
Intraoperative and postoperative in ICU (up to 24 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Severe mitral regurgitation and moderate or severe pulmonary hypertension Scheduled for mitral valve replacement surgery # Criteria of severe mitral regurgitation: Central jet MR >40% LA or holosystolic eccentric jet MR Vena contracta ≥ 0.7 cm Regurgitant volume ≥60 ml Regurgitant fraction ≥50% EROA ≥0.40 cm2 # Criteria of moderate and severe pulmonary hypertension: Moderate pulmonary hypertension; mean pulmonary artery pressure > 41 mmHg while, severe pulmonary hypertension; mean pulmonary artery pressure > 55 mmHg Mean pulmonary artery pressure > 40% of mean systemic blood pressure. Mean pulmonary artery pressure approximated from estimated systolic pulmonary artery pressure as following; mPAP= (estimated sPAP X 0.61) ± 2 Exclusion Criteria: Patients with multiple valve diseases -other than mitral valve-. Hemodynamic instability in the preoperative time (defined as acute requirement for vasoactive support or mechanical device). Contraindication to transesophageal echocardiography; esophageal stricture, tumor or diverticulum or active upper gastrointestinal bleeding Patients with hepatic or renal dysfunction. Patients with coagulopathy. Emergency surgeries.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ghada A Hassan, Professor
Organizational Affiliation
Faculty of Medicine - Menoufia University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mohamed A Salem, A. Professor
Organizational Affiliation
Faculty of Medicine - Menoufia University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Khaled M Gaballah, A. Professor
Organizational Affiliation
Faculty of Medicine - Menoufia University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mohammed O El Gouhary, Lecturer
Organizational Affiliation
Faculty of Medicine - Ain Shams University
Official's Role
Study Director
Facility Information:
Facility Name
Menoufia University Hospitals
City
Shibīn Al Kawm
State/Province
Menoufia
Country
Egypt

12. IPD Sharing Statement

Learn more about this trial

Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery

We'll reach out to this number within 24 hrs